1SRT Stock Chart & Stats
€190.60
€8.20(4.52%)
At close: 4:00 PM EST
€190.60
€8.20(4.52%)
Day’s Range― - ―
52-Week Range€87.00 - €302.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€13.65B
Enterprise Value€17.90K
Total Cash (Recent Filing)€306.90M
Total Debt (Recent Filing)€4.05B
Price to Earnings (P/E)80.1
Beta0.74
Next Earnings
Oct 22, 2026EPS Estimate
1.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.76
Shares Outstanding37,440,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.32
Price to Book (P/B)6.31
Price to Sales (P/S)4.82
P/FCF Ratio79.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5.37
Revenue Forecast (FY)€3.73B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables GrowthConsumables' consistent high-single-digit operational growth and multi-year double‑digit CAGR create a razor‑and‑blade revenue base. Recurring repurchases and customer lock‑in provide durable revenue visibility, stable margin contribution and predictable cash flows that underpin long‑term investment capacity.
High‑margin Bioprocess SolutionsBPS is the group's largest, high‑value segment: sustained ~32% underlying EBITDA margin with mid‑single‑digit growth supports strong free cash flow generation. Durable BPS profitability funds R&D, capex and market expansion, reinforcing Sartorius' competitive position in biomanufacturing technologies.
Improving Cash Generation And DeleveragingMaterial improvement in operating cash flow and free cash flow, alongside a lower net debt/EBITDA and rising equity ratio, enhances financial flexibility. Strong cash conversion provides a sustainable source for capex, R&D and further deleveraging, reducing long‑term balance‑sheet risk.
Bears Say
Elevated LeverageMeaningful absolute debt and a debt‑to‑equity near 1.6 leave leverage elevated for a medical instruments supplier. High gross leverage constrains strategic optionality, heightens interest expense and increases vulnerability to demand or margin shocks, limiting long‑term capital allocation flexibility.
Weak Net Margin / Bottom‑line ConversionLow TTM net margin despite healthier EBIT indicates weak conversion of operating profits to net income. This makes earnings sensitive to financing, tax, FX and mix shifts, reducing retained earnings for reinvestment and lowering resilience to prolonged cost or demand pressures.
Tariff & Customer Timing RiskUncertainty over US tariff refunds and postponed orders from two advanced‑therapy customers create structural timing and mix risk. Deferred high‑margin projects and refund timing can shift revenue recognition and depress margins across multiple quarters, adding persistent volatility to outcomes.
Sartorius News
1SRT FAQ
What was Sartorius AG’s price range in the past 12 months?
Sartorius AG lowest stock price was €87.00 and its highest was €302.00 in the past 12 months.
What is Sartorius AG’s market cap?
Sartorius AG’s market cap is €13.65B.
When is Sartorius AG’s upcoming earnings report date?
Sartorius AG’s upcoming earnings report date is Oct 22, 2026 which is in 88 days.
How were Sartorius AG’s earnings last quarter?
Sartorius AG released its earnings results on Jul 23, 2026. The company reported €1.29 earnings per share for the quarter, missing the consensus estimate of €1.364 by -€0.074.
Is Sartorius AG overvalued?
According to Wall Street analysts Sartorius AG’s price is currently Overvalued.
Does Sartorius AG pay dividends?
Sartorius AG does not currently pay dividends.
What is Sartorius AG’s EPS estimate?
Sartorius AG’s EPS estimate is 1.27.
How many shares outstanding does Sartorius AG have?
Sartorius AG has 37,440,000 shares outstanding.
What happened to Sartorius AG’s price movement after its last earnings report?
Sartorius AG reported an EPS of €1.29 in its last earnings report, missing expectations of €1.364. Following the earnings report the stock price went down -4.421%.
Which hedge fund is a major shareholder of Sartorius AG?
Currently, no hedge funds are holding shares in IT:1SRT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sartorius Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.95%
12-Months-Change
Fundamentals
Return on Equity
0.41%
Trailing 12-Months
Asset Growth
-4.25%
Trailing 12-Months
Company Description
Sartorius AG
Sartorius AG, founded in Göttingen, Germany in 1870, is a global supplier of advanced bioprocess solutions, laboratory products, and associated services. The company's diverse portfolio encompasses several critical areas: For biosensing and detection, it provides biosensors, compliance instruments, system software, label-free detection technologies, and SPR systems. In cell analysis, Sartorius offers live-cell analysis platforms, flow cytometry systems, and specialized cell analysis reagents and consumables. Its media and reagent segment includes a wide array of formulations for antibody and recombinant protein production, viral vaccines, regenerative medicine, and stem cell cultivation, along with downstream buffers, microcarriers, strong acids, bases, alcohols, and detergents. The company manufactures various bioreactor systems, from multi-parallel and benchtop units to single-use, stainless steel, cell culture, and microbial bioreactors, all supported by dedicated software applications. Its extensive filtration product line features membranes, blotting products, filter papers, and glass and quartz microfibre products, alongside a comprehensive range of filtration devices for ultrafiltration, sterile filtration, harvesting, analytical and diagnostic sample preparation, particle analysis, pharmaceutical applications, protein/DNA concentration, venting, clarification, and membrane chromatography. Sartorius also delivers solutions for process filtration, process chromatography, fluid management, and cutting-edge process analytical technology with data analytics. Complementary laboratory equipment includes industrial microbiology systems, water purification units, precision weighing and pipetting/dispensing systems, OEM components, and centrifuges. Beyond its products, Sartorius provides essential services such as bioprocess development and engineering, protein expression system optimization, media and process development, comprehensive testing, instrument support, and validation. These offerings primarily serve the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industrial sectors across the globe.
Technical Analysis
Evonik
―
GEA Group AG
―
Gerresheimer
―
Pfeiffer Vacuum Technology
―
STRATEC Biomedical
―